Halper Sadeh Investigates Sealed Air, Exact Sciences, and Olympic Steel for Potential Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Investigation Focus: Halper Sadeh LLC is investigating Sealed Air Corporation (NYSE: SEE) for potential violations of federal securities laws related to its sale to CD&R for $42.15 per share in cash, raising concerns about fiduciary duties to shareholders.
- Exact Sciences Sale: Exact Sciences Corporation (NASDAQ: EXAS) is being sold to Abbott for $105.00 per common share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures on behalf of shareholders.
- Olympic Steel Transaction: Olympic Steel, Inc. (NASDAQ: ZEUS) is selling to Ryerson Holding Corporation for 1.7105 shares of Ryerson stock per Olympic share, prompting Halper Sadeh LLC to explore legal remedies and protections for shareholders.
- Legal Services Offered: Halper Sadeh LLC offers legal services on a contingency fee basis, encouraging shareholders to consult for free regarding their legal rights and options, aiming to support and remedy the interests of defrauded investors.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
4 Buy
17 Hold
0 Sell
Hold
Current: 102.340
Low
50.00
Averages
95.50
High
105.00
Current: 102.340
Low
50.00
Averages
95.50
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
